Benda Ebei

Benda Ebei, officially Hubei Tongji Benda Ebei Pharmaceutical Co., Ltd., is a Chinese pharmaceutical company that serves as a core operating subsidiary of Benda Pharmaceutical, Inc. The company achieved global recognition through its majority acquisition of Shenzhen SiBiono GeneTech, the developer of Gendicine, which became the world's first commercially approved gene therapy for cancer in 2003. Benda Ebei operates a significant manufacturing base in Hubei Province, specializing in the production of conventional medicines, active pharmaceutical ingredients (APIs), and Traditional Chinese Medicines (TCM). Its product portfolio includes treatments for oncology, respiratory ailments, and metabolic diseases, supported by GMP-certified facilities for both small molecule and biologic production. Despite historical financial restructuring at the parent level, Benda Ebei continues to be an active player in the Chinese life sciences sector, maintaining its focus on innovative therapies and essential medicine manufacturing.